Although genetic alterations in TP53, EGFR, EML4-ALK, PIK3CA, and KRAS have been identified as biomarkers of lung cancer, difficulties remain in diagnosing, predicting the prognosis of, and treating lung cancer patients. This evidence concerns the gene KRAS and lung carcinoma.